Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR ® /BREO ® ELLIPTA ® and ANORO ® ELLIPTA ®. In addition, Innoviva retains a 15 percent economic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback